((2-(2-iodoethoxy)ethoxy)methyl)benzene | 88454-83-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ((2-(2-iodoethoxy)ethoxy)methyl)benzene
• 英文别名: 1-Iodo-7-phenyl-3,6-dioxaheptane；1-benzyloxy-5-iodo-3-oxapentane；{[2-(2-Iodoethoxy)ethoxy]methyl}benzene；2-(2-iodoethoxy)ethoxymethylbenzene
• CAS: 88454-83-5
• 化学式: C₁₁H₁₅IO₂
• 分子量: 306.143
• InChiKey: FOTGGLGFUDQCTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ((2-(2-iodoethoxy)ethoxy)methyl)benzene 在 盐酸 、 lithium hydroxide monohydrate 、 三叔丁基膦 、 potassium carbonate 、 lithium hexamethyldisilazane 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 sodium nitrite 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 12.5h， 生成 6-(2-(6-(2-(2-(benzyloxy)ethoxy)ethoxy)naphthalen-2-yl)-2H-tetrazol-5-yl)-2-naphthoic acid
  参考文献：
  名称：

  Fluorogenic, Two-Photon-Triggered Photoclick Chemistry in Live Mammalian Cells

  摘要：

  The tetrazole-based photoclick chemistry has provided a powerful tool to image proteins in live cells. To extend photoclick chemistry to living organisms with improved spatiotemporal control, here we report the design of naphthalene-based tetrazoles that can be efficiently activated by two-photon excitation with a 700 nm femtosecond pulsed laser. A water-soluble, cell-permeable naphthalene-based tetrazole was identified that reacts with acrylamide with the effective two-photon cross-section for the cycloaddition reaction determined to be 3.8 GM. Furthermore, the use of this naphthalene-tetrazole for real-time, spatially controlled imaging of microtubules in live mammalian cells via the fluorogenic, two-photon-triggered photoclick chemistry was demonstrated.

  DOI：

  10.1021/ja407867a
• 作为产物：
  描述：

  二乙二醇单苯甲醚 在 吡啶 、 氯化亚砜 、 sodium iodide 作用下， 以 乙醇 、 丙酮 、 苯 为溶剂， 反应 30.0h， 生成 ((2-(2-iodoethoxy)ethoxy)methyl)benzene
  参考文献：
  名称：

  Synthesis of lipophilic 18-crown-6 diacids for the membrane transport of alkaline-earth cations

  摘要：

  DOI：

  10.1021/jo00179a004

文献信息

• [EN] MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'OREXINE D'URÉE MACROCYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2022094012A1

  公开（公告）日：2022-05-05

  The present invention is directed to macrocyclic urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及宏环脲化合物，其是睡觉醒来素受体的激动剂。本发明还涉及所述化合物在潜在的涉及睡觉醒来素受体的神经和精神障碍和疾病的治疗或预防中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在涉及睡觉醒来素受体的这些疾病的预防或治疗中的用途。
• Renin-inhibitory dipeptides, their preparation and use
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0186977A2

  公开（公告）日：1986-07-09

  Compounds of formula (I): (wherein m is 0 or 1 and R1-R5 are a variety of organic groups) have the ability to inhibit the activity of renin and may thus be used to treat hypertension induced by failures in the renin-angiotensin system. They are prepared by conventional peptide synthesis routes.

  式(I)化合物（其中m为0或1，R1-R5为各种有机基团）具有抑制肾素活性的能力，因此可用于治疗肾素-血管紧张素系统失效诱发的高血压。 它们是通过传统的多肽合成路线制备的。
• Collie, Luke; Denness, James E.; Parker, David, Journal of the Chemical Society. Perkin transactions II, 1993, # 10, p. 1747 - 1758
  作者：Collie, Luke、Denness, James E.、Parker, David、O'Carroll, Fiona、Tachon, Christine

  DOI：——

  日期：——
• FYLES, TH. M.;MCGAVIN, C. A.;WHITFIELD, D. M., J. ORG. CHEM., 1984, 49, N 5, 753-761
  作者：FYLES, TH. M.、MCGAVIN, C. A.、WHITFIELD, D. M.

  DOI：——

  日期：——
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015000868A1

  公开（公告）日：2015-01-08

  A compound of formula (I) or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.